EZH2 and ovarian cancer: As overexpression of EZH2 has been shown to contribute to the development of acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo [156], then potentially NSCLC patients with either high BRCA1 or EZH2 levels might potentially benefit from treatments with poly(ADP-ribose) polymerase (PARP) inhibitors such as (DZNep), or could potentially be targeted to induce mIR-101.